DeCure for Multiple sclerosis

Over the past two decades, licensed treatments for multiple sclerosis have shown convincing effects only on relapse frequency, not on long-term disability progression. A 2013 review notes that while progress has been made, the limitations of current disease-modifying therapies remain clear, and several interventions are still in development. A separate 2000 review similarly summarises advances with available therapies and outlines results from studies of other drugs under investigation, but does not report any new approvals or breakthroughs from those trials.

Long-term data on intramuscular interferon beta-1a, summarised in 2013, rely on relapse rates, MRI parameters, and disability progression as key endpoints. The review does not provide new evidence that this drug alters the long-term course of the disease beyond these measures, and it emphasises that treatment decisions must now weigh long-term efficacy and safety on an individual basis as the number of available products grows.

Genetic susceptibility research, reviewed in 2002, confirms that multiple sclerosis has a strong genetic component, but the authors state plainly that these genetic data have not yet been applied to therapy. No gene-directed treatment is described. A 2020 gene expression study of CD8+ T cells identifies differentially expressed genes between MS patients and healthy controls, but this is a supplemental data file with no clinical results or therapeutic implications reported.

A 2022 Spanish case report describes one 39-year-old woman with relapsing-remitting MS who, after suboptimal response to alemtuzumab and ocrelizumab, received periodic plasmapheresis every three weeks as maintenance therapy. She remained clinically stable and had no new hospital admissions for acute attacks from February 2020 to March 2021. The authors conclude that more specific studies are needed before this can be considered a new maintenance treatment for patients refractory to drug therapies.